Drug Profile
Camizestrant - AstraZeneca
Alternative Names: [14C]AZD9833; AZ 14066724; AZD-9833Latest Information Update: 28 Feb 2024
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Amines; Antineoplastics; Azetidines; Fluorinated hydrocarbons; Hepatoprotectants; Isoquinolines; Pyrazolones; Pyridines; Small molecules
- Mechanism of Action Selective estrogen receptor degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III HER2 negative breast cancer
- Phase I Liver disorders
- No development reported Breast cancer
Most Recent Events
- 28 Feb 2024 No recent reports of development identified for phase-I development in Breast-cancer in United Kingdom (IV, Infusion)
- 28 Feb 2024 No recent reports of development identified for phase-I development in Breast-cancer in United Kingdom (PO, Liquid)
- 28 Feb 2024 No recent reports of development identified for phase-I development in HER2-negative-breast-cancer(In the elderly, Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater, In adults) in Japan (PO)